No Data
Jefferies Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $40
Oruka Therapeutics' Promising Long-Term Strategy and Advancements in Psoriasis Treatments Drive Buy Rating
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Oruka Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $41
Strong Growth Potential for Oruka Therapeutics Driven by Robust Financials and Promising Drug Pipeline
No Data
No Data
Stock_Drift : It’s not allowed north of the Mason Dixon line. Same with sugar in tea and Waffle Houses.
Stock_Drift : And I’m just kidding around.
MARKET-TEST-DUMMY OP Stock_Drift : Damn, that stings a little.
MARKET-TEST-DUMMY OP Stock_Drift : Absolutely! Enjoy it!
Stock_Drift MARKET-TEST-DUMMY OP : Just fun banter, I love the south, except Georgia.
View more comments...